Printer Friendly

New dose of Flexeril. (Products).

Flexeril (cyclobenzaprine) is now approved in a 5-mg tablet dose for use as an adjunct to rest and physical therapy for the relief of muscle spasm associated with acute, painful, musculoskeletal conditions. The drug is contraindicated in patients during the acute recovery phase of myocardial infarction or in patients with arrhythmias, heart block, conduction disturbances, congestive heart failure, allergies to cyclobenzaprine or other ingredients in Flexeril, hypothyroidism, or current or recent use (within 14 days after discontinuation) of monoamine oxidase inhibitors. For more information, contact McNeil Consumer & Specialty Pharmaceuticals, 888440-7903,
COPYRIGHT 2003 International Medical News Group
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2003 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Internal Medicine News
Date:May 1, 2003
Previous Article:Avoiding patient harm. (Products).
Next Article:Project seeks to develop electronic health record. (Planned for 2005).

Related Articles
New dose of Flexeril. (Products).

Terms of use | Privacy policy | Copyright © 2022 Farlex, Inc. | Feedback | For webmasters |